CONFERENCE DAY TWO

Thursday, November 6

8:15 am Registration & Morning Coffee

8:50 am Chair’s Opening Remarks

  • Fatima Scipione Vice President, Global Patient Affairs, Blueprint Medicines

Comprehensive Strategies for Paediatric Rare Disease Trials: Engagement, Retention, & Transition Solutions

9:00 am Putting Youth at the Center: Best Practices for Pediatric Engagement

  • Sabina Schmidt Goldstein-Becerra, Executive Director, International Cancer Advocacy Network (ICAN)

Synopsis

  • Learning how to authentically engage pediatric patients as active contributors in clinical research and innovation
  • Discovering strategies to create inclusive, age-appropriate materials, consent processes, and engagement tools that reflect young people's needs and voices
  • Understanding how a structured youth feedback loop, including iCAN’s Seal of Approval, ensures how materials and initiatives meet pediatric standards and expectations

9:30 am Improving Paediatric Trial Compliance & Retention by Supporting Caregivers

Synopsis

  • Targeting and engaging parents effectively as primary decision-makers to boost awareness and trust in paediatric rare disease trials
  • Providing tailored support to manage caregiver time constraints while ensuring critical safety monitoring without added burden
  • Highlighting effective caregiver support programs that reduce dropout rates and improve patient retention

10:00 am Session Reserved for Medical Research Network

10:30 am Morning Break & Networking

Innovating Trial Design: Enhancing Patient Inclusion & Flexibility in Rare Disease Trials

11:15 am Partnering with Patients: Co-Creating Clinical Trials to Shape Smarter Trial

  • Tricha Shivas Chief of Staff & Strategy, Foundation for Sarcoidosis Research
  • Brittany Davis Senior Director, Patient Advocacy & Insights, Avalyn Pharmaceuticals

Synopsis

  • Engaging patients and caregivers from the outset to co-develop protocols, endpoints, and eligibility criteria
  • Integrating patient insights to drive more inclusive designs, increase trial relevance, and boost enrolment
  • Avoiding misalignment by validating assumptions early and embedding the patient experience in study planning

11:45 am Operationalizing Strategies for Inclusive & Representative Clinical Trials in Rare Disease Research

  • LaShell Robinson Executive Director, Head Global Feasibility & Trial Equity, Takeda

12:15 pm Lunch Break & Networking

1:15 pm Decentralized Trials in Rare Disease: What’s Working & What’s Not?

Synopsis

  • Which aspects of decentralized trials (e.g. home nursing, remote monitoring, eConsent) are proving most viable in rare indications?
  • Where do challenges remain – such as diagnostics, sample collection, or maintaining data integrity?
  • How can we strike the right balance between virtual convenience and medical oversight?

Boosting Trial Completion Rates with Fair Compensation & Patient-Centric Support Strategies

1:45 pm Specialised Retention Strategies for Rare Disease Clinical Trials

  • Nanci Eannucci Senior Director, Site Engagement, Teva Pharmaceuticals

Synopsis

  • Exploring key barriers to long-term engagement and how to address emotional, logistical, and clinical challenges unique to rare disease populations
  • Examine successful models of decentralisation, flexibility, and patient support that reduce burden and prevent drop-out

2:15 pm Afternoon Break

2:45 pm Planning for Retention: Embedding Reimbursement & Support Strategies into Rare Disease Trials from the Start

Synopsis

  • Embedding patient-friendly reimbursement workflows into trial design from day one to avoid costly mid-study changes
  • Managing cross-border reimbursement challenges, including banking limitations and regional regulations
  • Evaluating the role of concierge services and home nursing to support retention, and the complexities of adding these services mid-trial
  • Reducing stress for patients and families by streamlining communications and minimizing administrative burden

3:15 pm Designing Fair & Flexible Compensation Models to Maximize Trial Participation

  • Diego Cortina Director, Global Pipeline & Value Evidence Strategy, Biogen

Synopsis

  • Assessing patient financial burdens beyond travel, childcare, lost wages, and more
  • The voice of the patient and caregiver as critical factor in shaping clinical meaningful endpoint selection
  • Balancing ethical considerations with practical incentives to encourage participation
  • Collaborating with payers and regulators to ensure compliance, transparency, and meaningful outcomes

3:45 pm Chair’s Closing Remarks

  • Fatima Scipione Vice President, Global Patient Affairs, Blueprint Medicines

3:50 pm End of Conference